Connect with us
The total shareholder return in 2020 was 19.3% in CHF and 18.1% in EUR, slightly below the performance of the underlying portfolio. In addition to Mersana...
More and more people are getting cancer. In Germany alone, doctors diagnose around half a million new cancer patients every year. But science is also making...
With a plan of building a premier innovative biopharma company and now a highly diversified portfolio, Bristol-Myers Squibb’s merger deal with Celgene is expected to become...
